Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Quarterly Report · 10-Q

CeriBell, Inc.

CBLLNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 10, 2026Accepted Aug 10, 2026, 4:50 PM EDTCIK 1861107Accession 0001193125-26-342574
Share

Company context

Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.

Current securities

Recent company filings

  1. 144 filingSep 8, 2026
  2. 144 filingAug 21, 2026
  3. 144 filingAug 21, 2026
  4. SCHEDULE 13G/A filingAug 14, 2026
  5. 144 filingAug 13, 2026

As-filed source

Primary evidence